The clinical validation data for the Genedrive HCV ID Kit will be presented at the conference by Dr Darragh Duffy from the Institut Pasteur in Paris, one of the world’s leading research centres.
Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.
The trials revealed the technology was highly accurate and performed well against the best-in-class device.
“The Genedrive HCV assay will allow decentralised laboratories to provide affordable onsite molecular testing for HCV that aligns with recent WHO testing guidelines," said chief executive David Budd.
“With the wider availability of generic direct acting antiviral agents, the drive in resource limited countries is to cost effectively identify and treat individuals with Hepatitis C.
“We believe that with the performance achieved by the Genedrive HCV assay, there is an opportunity to play a very meaningful role in this strategy.”
CE certification in the works
The molecular diagnostics firm recently submitted the HCV ID Kit for certification under the EU Medical Devices Directive, the receipt of which would green-light the commercialisation of the product in the EU.
Shares opened almost 3% higher at 43.7p on Tuesday.